<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629873</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-Chi-BEAC-HSCT</org_study_id>
    <nct_id>NCT03629873</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects</brief_title>
  <official_title>A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC&#xD;
      combining with auto-HSCT to treat aggressive lymphoma Subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of hematopoietic reconstitution</measure>
    <time_frame>15 days, 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Double-hit Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m^2 IVD d-6; Etoposide 150mg/m^2/d qd IVD d-5~-2; Cytarabine 150mg/m^2 q12h IVD d-5~-2; Cyclophosphamide 1.0g/m^2/d qd IVD d-5~-2</description>
    <other_name>Carmustine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Cytarabine</other_name>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Autologous hematopoeitic stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aggressive lymphoma subjects: diffuse large B cell lymphoma confirmed by&#xD;
             immunohistochemistry and aaIPI≥3; double-hit lymphoma, as first-line or second-line&#xD;
             consolidation therapy; peripheral T-cell lymphoma except ALK-positive type, as&#xD;
             first-line or second-line consolidation therapy; mantle cell lymphoma, as first-line&#xD;
             or second-line consolidation therapy.&#xD;
&#xD;
          2. Adequate organ system function including:&#xD;
&#xD;
             Creatinine clearance rate ≥ 80ml/min and creatinine &lt; 160μmol/L ALT/AST ≤ 2 upper&#xD;
             limit of normal Total Bilirubin &lt; 2 upper limit of normal FEV1、FVC and DLCO ≥ 50%&#xD;
             predictive value Left ventricular ejection fraction ≥ 50% No Symptomatic arrhythmia&#xD;
&#xD;
          3. Age 18-60 years, male and female&#xD;
&#xD;
          4. ECOG score 0-1&#xD;
&#xD;
          5. Number of neutrophil ≥ 1.5×10^9/L, number of platelet ≥ 70×10^9/L, concentration of&#xD;
             hemoglobin ≥ 90g/L, number of CD34+ cells ≥ 2.0×10^6/kg&#xD;
&#xD;
          6. Expected survival ≥ 12 weeks&#xD;
&#xD;
          7. Volunteered to participate in this study and signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have evidence of CNS lymphoma&#xD;
&#xD;
          2. Relapse after autologous hematopoietic stem cell transplantation&#xD;
&#xD;
          3. Active hepatitis B or hepatitis C virus infection&#xD;
&#xD;
          4. Severe active infection&#xD;
&#xD;
          5. HIV-infected persons&#xD;
&#xD;
          6. Liver cirrhosis or hepatic fibrosis&#xD;
&#xD;
          7. QTc &gt; 500ms&#xD;
&#xD;
          8. Have mental disorder or unable to sign informed consent&#xD;
&#xD;
          9. History of drug abuse and intemperance&#xD;
&#xD;
         10. Women who are pregnant or lactating or have breeding intent&#xD;
&#xD;
         11. The investigators believe that any increase in the risk of the subject or interference&#xD;
             with the results of the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Xu, Ph.D.</last_name>
    <phone>+86-25-68302182</phone>
    <email>xuwei10000@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematological Department, People's Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Xu, Ph.D.</last_name>
      <phone>+86-2568302182</phone>
      <email>xuwei10000@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

